{"id":"W4281645619","doi":"10.1056/evidoa2100070","title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","year":2022,"lang":"en","type":"article","venue":"NEJM Evidence","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1432,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Internal medicine; Confidence interval; Oncology; Regimen; Urology; Surgery; Cancer; Immunotherapy; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1253603055975009,"score_gpt":0.2842659688337804,"score_spread":0.1589056632362795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}